Randall G Fisher1, Davey M Smith2, Ben Murrell3, Ruhan Slabbert4, Bronwyn M Kirby5, Clair Edson6, Mark F Cotton7, Richard H Haubrich8, Sergei L Kosakovsky Pond3, Gert U Van Zyl9. 1. Division of Medical Virology, Department of Pathology, Faculty of Medicine and Health Sciences, Stellenbosch University, Francie van Zilj Drive, Parow 7500, South Africa. 2. Department of Medicine, University of California, San Diego, Stein Clinical Research Building #325 (mail code 0679), 9500 Gilman Drive, La Jolla, CA 92093, USA; San Diego Veterans Affairs Healthcare System, (Mail Code 8208), 150 W. Washington Street #100, San Diego, CA 92103, USA. 3. Department of Medicine, University of California, San Diego, Stein Clinical Research Building #325 (mail code 0679), 9500 Gilman Drive, La Jolla, CA 92093, USA. 4. Department of Genetics, Stellenbosch University, Private Bag X1, 7602 Matieland, South Africa. 5. Institute for Microbial Biotechnology and Metagenomics, New Life Sciences Building, 2nd Floor, Core 2, University of the Western Cape, Modderdam Road, P/Bag X17, Bellville 7530, South Africa. 6. Department Paediatrics and Child Health, Stellenbosch University and Tygerberg Children's Hospital, Francie van Zijl Drive, Parow 7500, South Africa. 7. Department Paediatrics and Child Health, Stellenbosch University and Tygerberg Children's Hospital, Francie van Zijl Drive, Parow 7500, South Africa; Children's Infectious Diseases Clinical Research Unit (KIDCRU) Ward J8, Tygerberg Hospital, Francie van Zijl Drive, Parow 7500, South Africa. 8. University of California, San Diego, AVRC, 220 Dickinson, Suite A, San Diego, CA 92103, USA. 9. Division of Medical Virology, Department of Pathology, Faculty of Medicine and Health Sciences, Stellenbosch University, Francie van Zilj Drive, Parow 7500, South Africa; National Health Laboratory Service, Tygerberg, Francie van Zijl Drive, Parow 7500, South Africa. Electronic address: guvz@sun.ac.za.
Abstract
BACKGROUND: Next generation sequencing (NGS) allows the detection of minor variant HIV drug resistance mutations (DRMs). However data from new NGS platforms after Prevention-of-Mother-to-Child-Transmission (PMTCT) regimen failure are limited. OBJECTIVE: To compare major and minor variant HIV DRMs with Illumina MiSeq and Life Technologies Ion Personal Genome Machine (PGM) in infants infected despite a PMTCT regimen. STUDY DESIGN: We conducted a cross-sectional study of NGS for detecting DRMs in infants infected despite a zidovudine (AZT) and Nevirapine (NVP) regimen, before initiation of combination antiretroviral therapy. Sequencing was performed on PCR products from plasma samples on PGM and MiSeq platforms. Bioinformatic analyses were undertaken using a codon-aware version of the Smith-Waterman mapping algorithm and a mixture multinomial error filtering statistical model. RESULTS: Of 15 infants, tested at a median age of 3.4 months after birth, 2 (13%) had non-nucleoside reverse transcriptase inhibitor (NNRTI) DRMs (K103N and Y181C) by bulk sequencing, whereas PGM detected 4 (26%) and MiSeq 5 (30%). NGS enabled the detection of additional minor variant DRMs in the infant with K103N. Coverage and instrument quality scores were higher with MiSeq, increasing the confidence of minor variant calls. CONCLUSIONS: NGS followed by bioinformatic analyses detected multiple minor variant DRMs in HIV-1 RT among infants where PMTCT failed. The high coverage of MiSeq and high read quality improved the confidence of identified DRMs and may make this platform ideal for minor variant detection.
BACKGROUND: Next generation sequencing (NGS) allows the detection of minor variant HIV drug resistance mutations (DRMs). However data from new NGS platforms after Prevention-of-Mother-to-Child-Transmission (PMTCT) regimen failure are limited. OBJECTIVE: To compare major and minor variant HIV DRMs with Illumina MiSeq and Life Technologies Ion Personal Genome Machine (PGM) in infants infected despite a PMTCT regimen. STUDY DESIGN: We conducted a cross-sectional study of NGS for detecting DRMs in infants infected despite a zidovudine (AZT) and Nevirapine (NVP) regimen, before initiation of combination antiretroviral therapy. Sequencing was performed on PCR products from plasma samples on PGM and MiSeq platforms. Bioinformatic analyses were undertaken using a codon-aware version of the Smith-Waterman mapping algorithm and a mixture multinomial error filtering statistical model. RESULTS: Of 15 infants, tested at a median age of 3.4 months after birth, 2 (13%) had non-nucleoside reverse transcriptase inhibitor (NNRTI) DRMs (K103N and Y181C) by bulk sequencing, whereas PGM detected 4 (26%) and MiSeq 5 (30%). NGS enabled the detection of additional minor variant DRMs in the infant with K103N. Coverage and instrument quality scores were higher with MiSeq, increasing the confidence of minor variant calls. CONCLUSIONS: NGS followed by bioinformatic analyses detected multiple minor variant DRMs in HIV-1 RT among infants where PMTCT failed. The high coverage of MiSeq and high read quality improved the confidence of identified DRMs and may make this platform ideal for minor variant detection.
Keywords:
HIV-1 drug resistance; Minor variant antiretroviral drug resistance mutations; Nevirapine; Next generation sequencing; Non-nucleoside reverse transcriptase inhibitor resistance; Prevention of mother to child transmission
Authors: Ben Murrell; Sasha Moola; Amandla Mabona; Thomas Weighill; Daniel Sheward; Sergei L Kosakovsky Pond; Konrad Scheffler Journal: Mol Biol Evol Date: 2013-02-18 Impact factor: 16.240
Authors: Michele W Tang; Soo-Yon Rhee; Silvia Bertagnolio; Nathan Ford; Susan Holmes; Kim C Sigaloff; Raph L Hamers; Tobias F Rinke de Wit; Herve J Fleury; Phyllis J Kanki; Kiat Ruxrungtham; Claudia A Hawkins; Carole L Wallis; Wendy Stevens; Gert U van Zyl; Weerawat Manosuthi; Mina C Hosseinipour; Nicole Ngo-Giang-Huong; Laurent Belec; Martine Peeters; Avelin Aghokeng; Torsak Bunupuradah; Sherri Burda; Patricia Cane; Giulia Cappelli; Charlotte Charpentier; Anoumou Y Dagnra; Alaka K Deshpande; Ziad El-Katib; Susan H Eshleman; Joseph Fokam; Jean-Chrysostome Gody; David Katzenstein; Donato D Koyalta; Johnstone J Kumwenda; Marc Lallemant; Lutgarde Lynen; Vincent C Marconi; Nicolas A Margot; Sandrine Moussa; Thumbi Ndung'u; Phillipe N Nyambi; Catherine Orrell; Jonathan M Schapiro; Rob Schuurman; Sunee Sirivichayakul; Davey Smith; Maria Zolfo; Michael R Jordan; Robert W Shafer Journal: J Infect Dis Date: 2013-06-15 Impact factor: 5.226
Authors: Avy Violari; Jane C Lindsey; Michael D Hughes; Hilda A Mujuru; Linda Barlow-Mosha; Portia Kamthunzi; Benjamin H Chi; Mark F Cotton; Harry Moultrie; Sandhya Khadse; Werner Schimana; Raziya Bobat; Lynette Purdue; Susan H Eshleman; Elaine J Abrams; Linda Millar; Elizabeth Petzold; Lynne M Mofenson; Patrick Jean-Philippe; Paul Palumbo Journal: N Engl J Med Date: 2012-06-21 Impact factor: 91.245
Authors: Jonathan Z Li; Roger Paredes; Heather J Ribaudo; Evguenia S Svarovskaia; Michael J Kozal; Katherine H Hullsiek; Michael D Miller; David R Bangsberg; Daniel R Kuritzkes Journal: AIDS Date: 2012-01-14 Impact factor: 4.177
Authors: Roger Paredes; Christina M Lalama; Heather J Ribaudo; Bruce R Schackman; Cecilia Shikuma; Francoise Giguel; William A Meyer; Victoria A Johnson; Susan A Fiscus; Richard T D'Aquila; Roy M Gulick; Daniel R Kuritzkes Journal: J Infect Dis Date: 2010-03 Impact factor: 5.226
Authors: Louise Kuhn; Gillian Hunt; Karl-Günter Technau; Ashraf Coovadia; Johanna Ledwaba; Sam Pickerill; Martina Penazzato; Silvia Bertagnolio; Claude A Mellins; Vivian Black; Lynn Morris; Elaine J Abrams Journal: AIDS Date: 2014-07-17 Impact factor: 4.177
Authors: Michael G Berg; Julie Yamaguchi; Elodie Alessandri-Gradt; Robert W Tell; Jean-Christophe Plantier; Catherine A Brennan Journal: J Clin Microbiol Date: 2015-12-23 Impact factor: 5.948
Authors: Sergio M de Almeida; Michelli F Oliveira; Antoine Chaillon; Indianara Rotta; Clea E Ribeiro; Ana Paula de Pereira; Davey Smith; Scott Letendre; Ronald J Ellis Journal: J Neurovirol Date: 2018-09-07 Impact factor: 2.643
Authors: Antoine Chaillon; Sara Gianella; Steven M Lada; Josué Perez-Santiago; Parris Jordan; Caroline Ignacio; Maile Karris; Douglas D Richman; Sanjay R Mehta; Susan J Little; Joel O Wertheim; Davey M Smith Journal: J Virol Date: 2018-01-17 Impact factor: 5.103
Authors: Sergio M de Almeida; Indianara Rotta; Clea E Ribeiro; Michelli F Oliveira; Antoine Chaillon; Ana Paula de Pereira; Ana Paula Cunha; Marise Zonta; Joao França Bents; Sonia M Raboni; Davey Smith; Scott Letendre; Ronald J Ellis Journal: J Neurovirol Date: 2017-02-28 Impact factor: 2.643
Authors: Antoine Chaillon; Masato Nakazawa; Joel O Wertheim; Susan J Little; Davey M Smith; Sanjay R Mehta; Sara Gianella Journal: J Virol Date: 2017-10-13 Impact factor: 5.103
Authors: Fred Kyeyune; Richard M Gibson; Immaculate Nankya; Colin Venner; Samar Metha; Juliet Akao; Emmanuel Ndashimye; Cissy M Kityo; Robert A Salata; Peter Mugyenyi; Eric J Arts; Miguel E Quiñones-Mateu Journal: Antimicrob Agents Chemother Date: 2016-05-23 Impact factor: 5.191
Authors: Sara Gianella; Sergei L Kosakovsky Pond; Michelli F Oliveira; Konrad Scheffler; Matt C Strain; Antonio De la Torre; Scott Letendre; Davey M Smith; Ronald J Ellis Journal: Virus Evol Date: 2016-08-03